Fabry Disease Patients with Higher Residual GLA Activity Respond Better to Galafold Treatment, Swiss Study Says
News
Nearly half of Fabry patients have amenable or responsive mutations to Galafold (migalastat) but show different responses to the therapy, according to a Swiss population study. The study found ... Read more